Printer Friendly

CALGENE CORRECTS MISLEADING REPORT

 DAVIS, Calif., Jan. 11 /PRNewswire/ -- Calgene Inc. (NASDAQ-NMS: CGNE) today declared that a weekend news report claiming Campbell Soup (NYSE: CPB) had backed away from food biotechnology was inaccurate and misleading.
 Calgene's relatis?hip with Campbell Soup has not changed," stated Roger Salquist, chairman and chief executive officer. "Calgene is proceeding on schedule with the planned 1993 introduction of its FLAVR SAVR(TM) tomato into North American fresh produce markets." Salquist added, "Neither Calgene nor Campbell Soup have made any decision as to whether genetically modified tomatoes provide an advantage for the consumer of processed tomato products. However, strong consumer preference for the fresh market FLAVR SAVR tomato has been consistently demonstrated in all of Calgene's market research."
 Calgene and Campbell Soup have had a relationship since 1985 involving tomato research. Calgene holds the exclusive rights to use FLAVR SAVR technology in fresh tomatoes in North America.
 -0- 1/11/93
 /CONTACT: Stephen Benoit of Calgene Fresh, 708-864-3333; or Carolyn Hayworth of Calgene, 916-753-6313/
 (CGNE CPB)


CO: Calgene Inc.; Campbell Soup ST: California IN: MTC FOD SU:

TM-SG -- SF008 -- 3604 01/11/93 14:19 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 11, 1993
Words:186
Previous Article:COLUMBIA ALUMINUM CORP. ANNOUNCES CLOSURE
Next Article:CHRISTIAN PURCHASING NETWORK ANNOUNCES SIX-FOLD INCREASE IN LANIER WORLDWIDE MARKET VENTURE
Topics:


Related Articles
CALGENE APPOINTS MOTRONI TO VICE PRESIDENT OF FINANCE; WAGSTER TO HEAD OPERATIONS AT CALGENE FRESH
CALGENE PROVIDES INFORMATION ON RECENT REGULATORY AND BUSINESS DEVELOPMENTS
CALGENE FRESH COMPLETES PRE-MARKET TESTING ON FLAVR SAVR(TM) TOMATO; DATA SUBMITTED TO FDA AND AVAILABLE TO THE PUBLIC
CALGENE CLARIFIES MISLEADING PRESS REPORTS ON ENZO LITIGATION
CALGENE, PLANT GENETIC SYSTEMS EXECUTE BROAD CROSS LICENSE AGREEMENTS; CALGENE GRANTS PLANT ANTISENSE LICENSE AND RECEIVES BT PATENT RIGHTS
CALGENE AND PFIZER FOOD SCIENCE ANNOUNCE RESEARCH COLLABORATION
GROUPE LIMAGRAIN LICENSES CALGENE TECHNOLOGIES TO PRODUCE PHARMACEUTICAL PROTEINS IN PLANTS
CALGENE COMPLETES STRATEGIC ALLIANCE WITH MONSANTO
CALGENE AND MONSANTO ANNOUNCE OILSEED CROSS LICENSING AGREEMENT
CALGENE ANNOUNCES PLANNED $50 MILLION EQUITY INVESTMENT BY MONSANTO

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters